title: Correlation of anti-idiotype network with survival following anti-G(D2) monoclonal antibody 3F8 therapy of stage 4 neuroblastoma.
abstract: BACKGROUND
  A transient human anti-mouse antibody response was associated with significantly longer survival [Cheung et al. (1998): J Clin Oncol 16:3053] following antibody 3F8 (Ab1) treatment. We postulate that the induction of an idiotype network which included anti-anti-idiotypic (Ab3) and anti-G(D2) (Ab3') responses is associated with tumor control.
  
  
  METHODS
  Thirty-four patients with stage 4 neuroblastoma (NB) diagnosed at > 1 year of age were treated with anti-G(D2) monoclonal antibody 3F8 at the end of chemotherapy
  
  
  RESULTS
  Long-term progression-free survival and overall survival correlated significantly with Ab3' andAb3, but not with non-idiotypic antibody responses. Only one of six individual specificities showed significant correlations with patient survival.
  
  
  CONCLUSIONS
  As in vitro correlates of idiotype network initiated by Ab1 treatment, Ab3 and Ab3' may provide convenient biologic endpoints for monoclonal antibody therapy of advanced NB, and a rationale for choosing specific anti-idiotypic antibodies for vaccine development.
authors: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. cheungn@mskcc.org
authors: N K
authors: NK
authors: Cheung
authors: H F
authors: HF
authors: Guo
authors: I Y
authors: IY
authors: Cheung
mesh_terms: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D011508:Chondroitin Sulfate Proteoglycans / Q000276:immunology*; D006801:Humans; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000097:blood / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D017027:Protein Tyrosine Phosphatases / Q000276:immunology*; D054633:Receptor-Like Protein Tyrosine Phosphatases, Class 5; D015996:Survival Rate
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011508:Chondroitin Sulfate Proteoglycans; C112746:dinutuximab; C516895:PTPRZ1 protein, human; D017027:Protein Tyrosine Phosphatases; C516896:Ptprz1 protein, mouse; D054633:Receptor-Like Protein Tyrosine Phosphatases, Class 5